Mantle Cell Non-Hodgkin’s Lymphoma


FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (05-31-2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (11-6-2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading